The head of clinical trials at China National Pharmaceutical Group Corp (Sinopharm) laboratories in Peru, German Malaga, has stated that Peru's clinical trials of Sinopharm's COVID-19 vaccine were temporarily suspended by the Peruvian National Institute of Health after a participant reported a decrease in muscle strength in his legs, CNN reported on Monday.

Malaga told CNN that the 64-year-old patient, with allegedly more than 20 years of badly-controlled diabetes, is in stable condition.

According to CNN, the reason for the symptoms cannot yet be determined and an investigation is ongoing.